RNS Number : 5077A

Schroder UK Public Private Tst plc

30 September 2020

30 September 2020

Half Year Report

Schroder UK Public Private Trust plc hereby submits its Half Year Report for the six months ended 30 June 2020 as required by the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 4 .2.

The Half Year Report will shortly be available to download from the Company's webpages. Please click on the following link to view the document:


The Company has submitted a copy of its Half Year Report to the National Storage Mechanism and it will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .


Gareth Faith

Schroder Investment Management Limited Tel: 020 7658 3847


Half Year Report and Accounts for the six months ended 30 June 2020

Chair's Statement

During the six month period to 30 June 2020 the net asset value fell 8.1% from 49.46p per share to 45.44p per share. The share price fell from 38.35p to 25.50p in the same period. However, it has shown signs of recovery since the end of the period and the current price is 27.68p (as at 28 September).

Since 31 March, downwards valuations have stabilised and whilst the NAV is down 8.1% since the 31 December year end, since 1 April the NAV has declined by 1.5%. There have also been some positive developments in individual stocks. Detailed analysis of changes in valuation, updates on holdings and the outlook may be found in the Portfolio Managers Review.


During the period, net debt decreased by GBP7.2 million, and as at 30 June 2020, gearing stood at 25.1% of NAV (net debt of GBP103.5 million). The board will continue to work with Schroders to reduce this level of gearing.

Shareholder engagement

Although the Company's AGM was held behind closed doors due to the government restrictions on public gatherings during the pandemic, we arranged a webinar with the portfolio managers which was well attended. The portfolio managers will present to shareholders again by webinar at 10am on 8 October 2020. If you would like to register for the event, please do so at the following link https://www.schrodersevents.com/suppretail .

For regular news about the Company, shareholders are also encouraged to sign up to the Portfolio Manager's investment trusts update by visiting the Company's website


In the event that shareholders have a question for the board, please email the Company Secretary ( amcompanysecretary@schroders.com ) or write to us at the Company's new registered office address (1 London Wall Place, London EC2Y 5AU).


Despite the challenges of the COVID-19 pandemic, the board is pleased that the portfolio managers have developed engagement with portfolio companies and are heavily focused on near-term objectives, including adjusting position sizes towards a more balanced portfolio, while reducing debt and supporting the companies in the portfolio.

Susan Searle


29 September 2020

Portfolio Manager's Review


-- NAV of 45.44p per share, a reduction of 1.5% since 31 March 2020 (46.13p per share) and 8.1% since 31 December 2019 (49.46p per share).

-- Portfolio continues to benefit from the significant weighting in healthcare companies which have proved resilient over the full half year period, including particularly strong performance in the second quarter.

-- Schroders (the 'Portfolio Manager') continues to provide support to the businesses in the portfolio to help them navigate the COVID-19 crisis and is focused on adjusting position sizes towards a more balanced portfolio whilst reducing the debt.

   --        Net debt of GBP103.5 million, down GBP7.2 million from 31 December 2019. 


The first half of 2020 has seen significant volatility across both public and private markets around the world. Public equity markets initially sold off very heavily as a result of the COVID-19 pandemic and the unprecedented actions taken by governments to mitigate the impact on human life by locking down entire economies. This has had a devastating impact on many companies which rely on footfall for trade. However, some business models have been less exposed or been swift to adapt to this new environment. Those businesses with the flexibility to operate digitally have taken advantage of the rapid shift in consumer behaviour, whilst more traditional operators have suffered severe disruption.

Following the initial lockdown, many economies have seen huge levels of support from central banks and governments around the world through the provision of enormous quantities of monetary and fiscal stimulus designed to provide stability as the global economy has battled to deal with the pandemic. This intervention has been well received by the public equity markets around the world as investors look to the future, with some markets now trading above their pre-COVID levels.

However, the positive sentiment now being seen in the public markets is not being felt across all sectors. As highlighted above, those businesses that have the flexibility to adapt, or business models that are less impacted by the pandemic are being rewarded with strong performance and in many cases robust valuations.

More broadly, the impact of COVID-19 varied by region and industry, the specific business model of a company and its financing situation. As a result, it is important to look at the idiosyncratic risks and opportunities associated with each individual holding from a bottom-up perspective. As highlighted in the first quarter announcement, the Company's portfolio has benefited from having a high proportion of technology and healthcare companies, including several companies that were actively aiding in the fight to overcome the COVID-19 pandemic.

Over this reporting period, the impact of the pandemic on the performance of the portfolio has been particularly evident in the relative development of the public and private segments of the portfolio. The Company's quoted holdings experienced a high level of market volatility in the initial aftermath of the pandemic as evidenced in the first quarter NAV announcement. However, these sharp declines in prices have been followed by quick recoveries giving rise to a much stronger performance in the second quarter.

By comparison, the values of the Company's unquoted holdings however have taken longer to fully reflect the impact of the current crisis which remained shrouded in uncertainty at the end of the first quarter. It is important to note that private asset values are a product of far more than simply delayed public market valuations. Fundamentally, private asset valuations are anchored on capturing idiosyncratic risks and returns of individual assets over longer investment periods. The nature of these valuation frameworks means that they are designed to provide comparative stability during times of market turbulence.

From the perspective of valuation, the Company's portfolio has performed particularly resiliently due to the outsized weighting in healthcare companies, that have only been moderately impacted by the pandemic, and in fact many have achieved significant operational progress during the period. This has resulted in several upward adjustments to valuations which have counterbalanced those sectors within the portfolio which have been most heavily impacted, such as Financials. As a result, the Company reports relatively stable performance in the second quarter with the NAV reduced by 1.5%.

As Portfolio Manager, we have been actively adapting to the impact of the economic downturn across the portfolio and working intensely with each individual portfolio company management team to ensure that each business is best placed to cope with the demands of the current environment and seize opportunities where they may arise.

Financial Performance

 (GBPm)^                           Quoted*  Unquoted   Net Debt   Other      NAV 
 Value at 31.12.19                   134.3     426.8    (110.7)   (1.0)    449.4 
--------------------------------  --------  --------  ---------  ------  ------- 
 + Investments                         0.1       1.9      (2.0)       -        - 
--------------------------------  --------  --------  ---------  ------  ------- 
 - Realisations                      (5.8)     (6.2)       12.0       -        - 
--------------------------------  --------  --------  ---------  ------  ------- 
 +/- Fair value gains/ (losses)      (3.7)    (42.9)          -       -   (46.6) 
--------------------------------  --------  --------  ---------  ------  ------- 
 +/- FX gains/(losses)                 2.5      10.0          -       -     12.5 
--------------------------------  --------  --------  ---------  ------  ------- 
 +/- Costs and other movements           -         -      (2.8)     0.3    (2.4) 
--------------------------------  --------  --------  ---------  ------  ------- 
 Value at 30.06.20                   127.4     389.6    (103.5)   (0.7)    412.9 
--------------------------------  --------  --------  ---------  ------  ------- 

^Source: Administrator, FX gains/(losses) provided by the AIFM.

*As in the FY2019 annual report, Rutherford Health is reported as a quoted holding despite being fair value priced by the AIFM.

The half yearly NAV as at 30 June 2020 was GBP412.9 million or 45.44p per share. This reflects a like-for-like decrease of -1.5% compared with the NAV as at 31 March 2020 and a decrease of -8.1% since 31 December 2019.

The half year NAV return of -8.1% comprised:

   --           Quoted holdings* -0.8% 
   --           Unquoted holdings -9.5% 
   --           FX impact +2.8% 
   --           Costs and other movements -0.5% 

During the half year period, and despite the COVID-19 global market sell-off during the first quarter, the Company's quoted holdings saw a moderate decline in value of 3%, reversing part of the near 16% fall in the first quarter. In comparison, the FTSE AIM All-Share Index declined by 7.8% during the same period (Source: LSE website). The largest single contributor to performance in the quoted holdings was Autolus Therapeutics whose listed share price increased 20%, a recovery of 171% during the second quarter. In June 2020, the Company presented new data highlighting encouraging progress with its AUTO1 programme, a CAR-T cell therapy programme for relapsed / refractory adult Acute Lymphoblastic Leukaemia. The portfolio also benefited from similar share price reversals from other quoted holdings in the second quarter including Idex Biometrics +133%, Reneuron Group +45% and Mereo Biopharma +150%. The largest detractor from performance in the quoted holdings was Evofem Biosciences which declined 54%, predominantly due to its listed share price falling 47% in the second quarter. Following the receipt of FDA approval for the company's primary asset, a non-hormonal contraceptive, the market was disappointed by the scale of fund raising, at a significant discount to the share price, in order to meet the costs of a planned marketing campaign.

Despite the relative strength of the unquoted holdings in the first quarter, this segment of the portfolio experienced a further decline in the second quarter as the full impact of COVID-19 became reflected in portfolio valuations (as provided by the AIFM). As a result, the value of the Company's unquoted holdings declined 10% over the half year. The largest single positive contributor to performance in the unquoted holdings was Inivata which achieved a major milestone with the announcement of its strategic collaboration and investment from NeoGenomics, a leading US-based cancer diagnostics and services company. The most notable negative contributor to performance continued to be the downward valuation adjustments in the Financials sector, which has been most heavily impacted by COVID-19. In this regard, the largest change in valuation implemented by the Company's AIFM was the downwards adjustment to the holding in Atom Bank to reflect a contraction in the valuation metrics of its private and public market comparables - this peer group declining by greater than 35% since the Company's last investment date. The valuation changes in Financials also includes a downwards valuation adjustment to the holding in Ratesetter which experienced marketplace and funding headwinds due to the economic uncertainty caused by COVID-19, culminating in an acquisition offer from Metro Bank in the third quarter (See the Company Updates section for further details).

As mentioned earlier, more positively, the portfolio continued to benefit from the significant weighting in Health Care, representing of 58% gross asset value as at 31 Dec 2019, which delivered a positive net contribution in the second quarter. As did the portfolio's weighting in Technology, albeit from a lower base.

During the period, the portfolio also benefited from the decline in the value of sterling relative to the US dollar by 7.2% which resulted in an appreciation of the value of the Company's dollar-denominated assets.

Investment Activity

As part of our previously stated intention to move the portfolio toward a greater balance of sectors, stages and position sizes, the Company completed several realisations over the first half of the year. Within the private equity holdings, this included the partial realisation of the Company's holding in Oxford Nanopore as part of a strongly supported fundraise at an attractive valuation, and the full realisation of the holding in Yoyo Wallet in a previously agreed transaction.

Within the public equity holdings, we also moderately reduced various positions which had rebounded strongly in the second quarter or were otherwise considered oversized relative to our conviction levels. These limited realisations have mainly been used to meet more compelling opportunities to provide funding to some of the private companies held, whilst also ensuring that net debt levels are gradually reduced.

During the second quarter, the Company also completed the first tranche of a follow-on investment into a private healthcare holding alongside other existing shareholders. The transaction related to an existing commitment of the Company, agreed by the previous portfolio manager, which we supported to protect long-term value which otherwise would have been significantly diluted. The second tranche is expected to complete before the year end. This is the Company's penultimate such financial commitment related to follow-on funding agreed by the previous portfolio manager with the final transaction due to be reported in the third quarter. While the specific company remains unnamed due to commercial sensitivity, it is important to highlight that we intend to move towards increasing the level of disclosure as we progress with our repositioning.

In line with the board's commitment to reducing gearing over time, surplus funds were used to pay down the Company's gearing facility. As at 30th June 2020, net debt stood at GBP103.5 million or 25.1% of NAV.


Clearly the first half of 2020 has presented challenges, however we are pleased with the dialogue and relationships that we have developed with the portfolio companies since taking on portfolio management of the Company in December 2019.

As highlighted in the first quarter update, we have been heavily focused on achieving our near-term objectives. Firstly, we have been working closely with the companies within the portfolio to support operational decision-making in navigating the current economic turbulence and helping to identify opportunities that may arise from the COVID-19 crisis. In addition, the focus on adjusting position sizes towards a more balanced portfolio, whilst reducing debt, also remains front of mind and we hope to be able to provide further colour on the progress being made here soon.

We recognise that economic uncertainty persists as governments around the world continue to grapple with the most appropriate policy responses to the ongoing coronavirus pandemic. Case numbers have clearly risen again in numerous regions in the second half of 2020, including in the UK, which to some extent is itself likely to reflect a degree of recovery in social movement and working practices compared to the first half of the year. We are monitoring the situation closely with regard to any impact on portfolio companies from these continuing events, noting that the substantive adjustments already made to company structures will be equally relevant in a second wave of this pandemic.

Whilst repositioning the portfolio and reducing debt is a clear priority, it is also important to continue to support the companies in the portfolio as they continue to develop and grow. We expect to announce several significant operational milestones from companies in the portfolio in the second half of 2020 and we are excited about being able to communicate these developments if they materialise as expected.

We intend to continue to support the portfolio both financially and operationally, within the constraints of the Company's available liquidity, whilst also seeking other like-minded co-investors who we believe can add value to the portfolio companies over the longer term. We have built a good working relationship with our debt provider and maintain a regular dialogue. As such we anticipate being able to make targeted follow-on investments into some portfolio companies over the next six months and we will communicate these to the market as appropriate.

Company Updates

Rutherford Health: Announced Development Framework Agreement with Equitix, Diagnostics Services Agreement with Somerset NHS Foundation Trust and the commencement of patient treatment at the new Rutherford Cancer Centre North West

In June 2020, Rutherford Health announced that it has entered into a Development Framework Agreement with Equitix, an investor, developer and long-term fund manager of core infrastructure assets in the UK and Europe. Under the terms of the Agreement, Rutherford and Equitix will establish up to five new diagnostic facilities in the UK with an estimated value of approximately GBP55 million. Equitix will have the exclusive right to provide funding to establish special purpose vehicles to construct and own the diagnostic centres which will be operated by Rutherford Infrastructures (a wholly owned subsidiary). Rutherford Diagnostics, also a wholly-owned subsidiary, will provide diagnostic services. Each centre will provide a variety of diagnostics services to NHS and private patients including Positron Emission Tomography-Computed Tomography, Magnetic Resonance Imaging, Computed Tomography, Ultrasound, Endoscopy, X-Ray and other relevant diagnostic services.

In July 2020, Rutherford announced the first partnership under the Equitix Agreement with Somerset NHS Foundation Trust whereby the Company will provide a dedicated facility in Taunton. The Service Agreement is expected to commence in the second half of 2021 for a 5-year minimum term, extendable to 10 years, subject to the achievement of certain service levels, and carries minimum revenue of approximately GBP 1.9m per annum.

At the very end of the same month, the company also announced that it has commenced treating patients at the new Rutherford Cancer Centre North West, in Liverpool. This is the fourth centre in the Rutherford Health network. The centre has been approved by the Care Quality Commission to initially offer patients Systemic Anti-Cancer Therapy (SACT) services which includes chemotherapy, immunotherapy, targeted therapies, symptom control as well as blood tests, oncology nurse consultation and supportive therapies. The centre will also offer MRI diagnostic services. The facility will eventually offer comprehensive cancer services with plans to expand services later this year to include radiotherapy, mammography and ultrasound with high energy proton beam therapy coming online early next year. The Liverpool centre will also be the first in the UK to use an MR Linac machine, which combines an MRI scanner and a linear accelerator, manufactured by Elekta. This delivers targeted radiotherapy that can treat hard to reach tumours.

Atom Bank: Released its 2019/2020 Annual Report

In September 2020, Atom Bank released its 2020 Annual Report detailing progress against its key operational, financial and strategic objectives over the year to March 2020. In particular, the company disclosed the substantial progress achieved in redeveloping its banking stack and transitioning to the cloud. A key long-term investment which is intended to accelerate the speed, agility, data management and insight delivery in support of new product launches, such as the Instant Access Saver (IAS) account currently in production. One indication of the success of this project has been the consistently high customer ratings, including recognition as Trustpilot's most trusted UK bank, Net Promoter Scores in excess of +75 and at the time of writing, an App store rating of 4.7 across both Android and iOS.

During the financial year, Atom took steps to improve asset yields by increasing its lending to SMEs and refocusing its offer to residential mortgage customers. The company now has a larger and more granular balance sheet which affords more efficient liquidity management with consequent benefits to net interest income. The result is an underlying net interest income improvement over the year with momentum that is expected to continue.

In July 2020, Atom also completed its third residential mortgage-backed securitisation in order to support continued growth. The transaction was backed by GBP770m of mortgage loans and generated a substantial regulatory capital release. Atom is in a strong position and poised to accelerate its growth, leading to an expectation that it will be looking to add new capital in due course to continue scaling its capabilities.

Looking ahead to 2021, Atom intends to continue building out its inventory of products, widening its distribution and enhancing its automation capabilities in order to further enhance its customer experience and cost efficiency credentials. The actions taken by the business in the wake of the COVID-19 pandemic are intended to ensure that Atom is well placed to scale and to grow profitably, even in the face of present economic uncertainty.

Oxford Nanopore: Announced co-development of a highly scalable solution for COVID-19 detection and engagement at London Calling 2020

In June 2020, Oxford Nanopore announced its partnership with Group 42, an AI and cloud computing company based in the United Arab Emirates, to develop a population-scale technology to rapidly and accurately detect SARS-CoV-2, the virus that causes COVID-19. The end-to-end solution developed by G42 and Oxford Nanopore is expected to dramatically reduce the complexity of mass screening. The technology uses the LamPORE assay and Oxford Nanopore's rapid sequencing platform, in combination with the high-throughput automation, sample processing and reporting workflows developed by G42. The solution is now being incorporated into the UAE national testing strategy. Over a ramp-up period in the G42 sequencing facility in Abu Dhabi, the program is expected to scale to hundreds of thousands of samples daily. G42 and Oxford Nanopore are working on the production capacity for the global deployment of this technology.

In June 2020, Oxford Nanopore also hosted its London Calling conference dedicated to scientific research using nanopore DNA/RNA sequencing. Since 2015, this event has been a forum for people across numerous fields of research to meet and share how they're using nanopore sequencing in their work, encompassing everything from clinical research to plant genomics to bioinformatics. This year it took a very different format, going online for the first time ever. The event attracted 5,500 people tuning in to see the action, either live or on-demand, over two-and-a-half days of presentations, discussion and networking.

BenevolentAI: Highlighted further clinical data in support of its AI-derived hypothesis for Baricitinib as a potential treatment for COVID-19

In July 2020, BenevolentAI highlighted further clinical data in support of its AI-derived hypothesis for baricitinib as a potential treatment for COVID-19. The research, conducted in partnership with Eli Lilly, who own baricitinib, includes data studying the dual basis of baricitinib's effect on patients with bilateral COVID-19 pneumonia who presented with severe disease. The Company believes this research provides further validation of its AI-derived hypothesis of the previously unknown anti-viral activity effect of baricitinib, in addition to its predicted effects on reducing the cytokine storm. When treated with baricitinib, hospitalised COVID-19 patients showed improvement in cough, fever, and a reduction in inflammatory markers and SARS-CoV-2 viral load, data that has been replicated elsewhere in single-arm studies. The results of randomised trials, including the recently initiated global placebo-controlled study, are expected in the next few months.

In early February, the BenevolentAI team published its research finding that an oral, once daily medicine, baricitinib, normally used to treat adult rheumatoid arthritis, may be useful in both reducing viral propagation in cells, and to mitigate the cytokine signalling seen in the hyper inflammatory stage of the disease. Since these findings were first published in The Lancet and The Lancet Infectious Diseases, baricitinib has been administered to patients in more than 12 clinical trials worldwide, including large global trials by the NIAID and Eli Lilly. Following the initiation of clinical testing in April, baricitinib has been used in investigator-led trials as a therapy in more than 800 patients with positive preliminary results.

Inivata: Announced US commercial launch of InVisionFirst(R)-Lung

In June 2020, following its earlier strategic collaboration announced with NeoGenomics, Inivata announced the commercial launch of its InVisionFirst(R)-Lung liquid biopsy test in the US. InVisionFirst-Lung is a ctDNA next-generation sequencing liquid biopsy assay testing 37 genes relevant to the care of advanced non-small cell lung cancer (NSCLC). The test covers all National Comprehensive Cancer Network (NCCN) guideline-recommended genomic drivers with FDA-approved targeted therapies for NSCLC. InVisionFirst-Lung results are delivered within seven calendar days and the test is covered by Medicare and various private insurance payers for patients with advanced NSCLC meeting certain clinical criteria.

Mission Therapeutics: Announced $15m fundraise and expanded relationship with Pfizer

In July 2020, Mission Therapeutics announced that it has raised $15m (GBP12m) of equity investment in a funding round led by existing investor Pfizer Ventures, the venture capital arm of Pfizer. The new capital will support development of Mission's leading DUB platform, as well as growth of its pipeline of DUB inhibitor programmes. Mission and Pfizer Inc. also announced the expansion of their relationship by entering into an evaluation and option agreement for DUB target validation.

Mafic: Announced the start of operations at world's largest basalt fiber production facility

In July 2020, Mafic USA announced the commencement of operations at its new basalt fiber production facility in Shelby, North Carolina. The facility is the world's largest and the first such in North America. During the month, the team completed the highly calibrated process of starting-up the plant's furnace and began melting basalt rock and pulling the first fiber. The company expects to begin producing products for sale in early August.

This operational milestone marks a major step forward in the company's goal to bring basalt fiber to North American markets and produce on a commercially viable scale. Mafic began construction of its $20 million facility, located 45 miles from Charlotte, North Carolina, in 2016. The new facility is expected to be capable of producing 6,000 metric tons of basalt fiber annually, nearly 30 percent of the current global output of basalt fiber. Mafic is looking to commercialise basalt fibers for a wide array of industrial applications because of their strength and ability to replace materials susceptible to corrosion. The material has been used for decades, but until now, it has been produced in limited quantities. Mafic's goal is to bring the large-scale production of basalt fiber to several markets, including the construction, automotive, and thermal markets among others.

Autolus Therapeutics: Presented data at the 2020 EHA25 Virtual Congress and American Society of Clinical Oncology Annual Meeting 2020

Autolus Therapeutics has provided updates on its two most advanced programmes. In June 2020, the company presented new data highlighting progress on its AUTO1 programme at the European Hematology Association EHA25 Virtual Congress. AUTO1 is the company's CAR-T cell therapy programme for relapsed / refractory adult Acute Lymphoblastic Leukaemia. The company also provided an update on its AUTO3 CAR-T cell therapy programme for DLBCL (Diffuse Large B-Cell Lymphoma) at the 2020 Annual Meeting of the American Society of Clinical Oncology.

With regards to AUTO1, the company reported interim data from its ongoing study in the US and UK for treatment of adult Acute Lymphoblastic Leukaemia. The data showed good tolerance, with no patients experiencing Cytokine Release Syndrome of grade three or higher, and only low (and resolved) incidences of neurotoxicity. An encouraging 84% of patients experienced MRD-negative CR (Minimum Residual Disease Negative Complete Remission) after one month, and Event Free Survival rates at six months stand at 62%. These data overall demonstrate encouraging clinical efficacy and durability as well as limited safety concerns. From an operational perspective, product manufacturing was 100% successful for all patients for whom this was attempted. The company announced that enrolment of patients had been affected by COVID-19 in selected sites in the US and the UK but confirmed that the AUTO1 programme is on track, with further data expected later in 2020, and full data from the pivotal study expected by the end of 2021.

With regards to AUTO3, for adult DLBCL (Diffuse Large B-Cell Lymphoma), following encouraging tolerance and safety data, the company announced an expansion cohort to assess the feasibility of AUTO3 in the outpatient setting as part of a current study. Successful treatment in an outpatient setting would significantly increase the addressable market for this therapy. The next results from this programme are to be announced at the European Society for Medical Oncology Virtual Congress in September 2020, at the time of this report going to press, with a go/no-go decision on progressing to a Phase 2 pivotal study expected in the second half of 2020.

The company management continues to guide that cash of $212m will take it into 2022.

Kymab: Announced Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis

In August 2020, Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, announced that the primary endpoints in its Phase 2a (NCT03754309), randomized, double-blinded, placebo-controlled study have been met.

The proof of concept study, conducted across 20 European sites, evaluated the efficacy, safety and tolerability of KY1005 in 88 adults with moderate to severe atopic dermatitis whose disease could not be adequately controlled with topical corticosteroids. Patients were randomised into one of two dose groups of KY1005 or placebo and treated for 12 weeks. The primary endpoint was assessed 4 weeks later. Data from the study will be published in the fourth quarter of this year.

"The data from this atopic dermatitis study is extremely promising," said Simon Sturge, Chief Executive Officer. "Moderate to severe atopic dermatitis is a severe, debilitating disease. We are very encouraged by what we have seen and look forward to the long-term results from an assessment out to 6 months after the last dose to evaluate the persistence of response. Not only do these data validate KY1005 as a potential novel therapeutic for the treatment of atopic dermatitis, they also provide a platform to explore its effect in multiple other immune-mediated diseases."

Seedrs: Announced partnership with Capdesk to facilitate secondary liquidity in private companies

In June 2020, Seedrs announced its partnership with equity management platform, Capdesk. Thus, creating a unique secondary liquidity offering, serving the needs of the wider market with the ability to trade shares in private companies.

The Seedrs Secondary Market has been enhanced significantly and grown quickly since its launch in 2017. In May, the market surpassed GBP1m of shares traded in a month for the first time, with Revolut share sales topping the list for the most shares listed and sold. Now, companies outside the Seedrs portfolio who use Capdesk for their cap table and equity management systems will be able to access the Seedrs Secondary Market.

Reaction Engines: Announced new Strategic Partnership Agreement with Rolls-Royce

In August, Reaction Engines and Rolls-Royce plc announced a new strategic partnership agreement to develop high-speed aircraft propulsion systems and explore applications for Reaction Engines' thermal management technology within civil and defence aerospace gas turbine engines and hybrid-electric systems.

Additionally, Rolls-Royce disclosed a further investment in Reaction Engines as part of a wider funding round. The two companies have been working together since 2018, including on the first phase of a UK Ministry of Defence contract to undertake design studies, research, development, analysis and experimentation related to high-Mach advanced propulsion systems.

"This strategic partnership is about developing market ready applications for Reaction Engines' technology in next generation engines and is a significant step forward for our technology commercialisation plans," said Mark Thomas, Chief Executive of Reaction Engines. "Our proprietary heat exchanger technology delivers incredible heat transfer capabilities at extremely low weight and a compact size. We look forward to expanding our international collaboration with Rolls-Royce, a global leader in power systems, to bring to market a range of applications that will transform the performance and efficiency of aircraft engines, enable high speed - supersonic and hypersonic - flight and support the drive towards more sustainable aviation through innovative new technologies."

Spin Memory: Announced an extension of its Series B funding round

In July 2020, Spin Memory announced an extension of its Series B funding round, having received additional investment of $8.25m from its major investors including Arm, Applied Ventures, LLC (the venture capital arm of Applied Materials, Inc.) and Abies Ventures (Abies), as well as the company's founding investor, Allied Minds.

As the industry demand for high-speed, low-leakage, non-volatile memory continues to grow, Spin Memory is a pioneer in bringing MRAM closer and closer to SRAM-like performance as a new mainstream memory solution for applications such as autonomous driving, artificial intelligence and edge computing. The company is bolstered by over 250 patents, a commercial agreement with Applied Materials, and a licensing agreement with Arm.

ReNeuron Group: Released positive data in retinal clinical trial and announced expanded regulatory approvals

In June 2020, ReNeuron Group announced further positive data from its Phase 2a clinical trial of stem cell treatment for Retinitis Pigmentosa (RP), a group of hereditary diseases of the eye that cause progressive loss of sight leading to eventual blindness.

The latest available data indicates ongoing clinically meaningful benefit to eyesight observed at all time-points up to longest-available eighteen months since initial treatment, as measured by the number of letters read on an ETDRS chart (the standardised eye chart used to measure visual acuity in clinical trials).

Also in June 2020, the Company announced that it had received regulatory approval from both the U.S. Food and Drug Administration (FDA) and UK Medicine and Healthcare Products Regulatory Agency (MHRA) to expand its ongoing Phase 2a clinical study to treat patients with RP at a higher dose level. These approvals will enable the treatment of up to a further nine patients in the Phase 2a extension segment of the study (beyond the ten Phase 2a patients already treated), almost doubling the patient cohort. The company announced that it intends to commence treating patients shortly in both the US and the UK under the revised approved study protocol, subject to a continued easing of COVID-19 related restrictions at the relevant clinical sites.

The company expects to have sufficient data from this expanded Phase 2a clinical trial to enable it to seek approval in the second half of 2021 to commence a single pivotal clinical study with its stem cell therapy candidate in RP.

LIGNIA Wood Company: LIGNIA Yacht selected as Boating Industry Top Product 2020

In May 2020, LIGNIA Wood Company's high-performance, sustainable timber for yacht decking, LIGNIA Yacht, was selected by the editors of Boating Industry magazine as a Top Product for 2020. This award follows LIGNIA Yacht's award wins in 2019 at IBEX and METSTRADE.

Ratesetter: Metro Bank announced agreement to acquire Ratesetter

In August 2020, Metro Bank PLC announced that it had agreed to acquire Retail Money Market LTD ("RateSetter") for an initial consideration of GBP2.5 million, with additional consideration of up to GBP0.5 million payable 12 months after completion subject to the satisfaction of certain criteria and further consideration of up to GBP9 million payable on the third anniversary of the completion of the transaction, subject to the satisfaction of certain key performance criteria. The acquisition does not include RateSetter's holding in RateSetter Australia which is being retained by RateSetter shareholders. The acquisition is conditional upon approval from the Financial Conduct Authority and shareholders holding at least 60 percent of RateSetter's shares acceding to the relevant transaction documents and is expected to close by the fourth quarter this year. The board of directors of RateSetter unanimously recommended the transaction.

On 14 September 2020, Metro Bank announced the acquisition of RateSetter, following receipt of shareholders' and regulatory approval.

Schroder Investment Management Limited

29 September 2020

Securities named are for illustrative purposes only and should not be viewed as a recommendation to buy or sell.

Investment Portfolio as at 30 June 2020

The 20 largest investments account for 90.8% of total investments by value (30 June 2019: 83.0% and 31 December 2019: 88.7%).

                                    Quoted/       Industry   Fair value  investments 
 Holding                           unquoted         Sector      GBP'000            % 
-------------------------------  ----------  -------------  -----------  ----------- 
 Rutherford Health                   Quoted    Health Care       80,811         15.6 
-------------------------------  ----------  -------------  -----------  ----------- 
 Oxford Nanopore                   Unquoted    Health Care       68,707         13.3 
-------------------------------  ----------  -------------  -----------  ----------- 
 Atom Bank                         Unquoted     Financials       56,772         11.0 
-------------------------------  ----------  -------------  -----------  ----------- 
 Benevolent Al                     Unquoted     Technology       33,507          6.5 
-------------------------------  ----------  -------------  -----------  ----------- 
 Immunocore                        Unquoted    Health Care       26,980          5.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 Inivata                           Unquoted    Health Care       24,963          4.8 
-------------------------------  ----------  -------------  -----------  ----------- 
 Autolus Therapeutics                Quoted    Health Care       22,981          4.4 
-------------------------------  ----------  -------------  -----------  ----------- 
 Carrick Therapeutics              Unquoted    Health Care       18,533          3.6 
-------------------------------  ----------  -------------  -----------  ----------- 
 Kymab                             Unquoted    Health Care       16,971          3.3 
-------------------------------  ----------  -------------  -----------  ----------- 
 Mafic                             Unquoted    Industrials       16,196          3.1 
-------------------------------  ----------  -------------  -----------  ----------- 
 Industrial Heat                   Unquoted    Industrials       14,326          2.8 
-------------------------------  ----------  -------------  -----------  ----------- 
 Ombu                              Unquoted    Industrials       14,024          2.7 
-------------------------------  ----------  -------------  -----------  ----------- 
 Reaction Engines                  Unquoted    Industrials       12,500          2.4 
-------------------------------  ----------  -------------  -----------  ----------- 
 Mission Therapeutics              Unquoted    Health Care       10,117          2.0 
-------------------------------  ----------  -------------  -----------  ----------- 
 Federated Wireless                Unquoted     Technology        9,774          1.9 
-------------------------------  ----------  -------------  -----------  ----------- 
 Spin Memory                       Unquoted     Technology        9,429          1.8 
-------------------------------  ----------  -------------  -----------  ----------- 
 Genomics                          Unquoted    Health Care        9,045          1.7 
-------------------------------  ----------  -------------  -----------  ----------- 
 Seedrs                            Unquoted     Financials        8,749          1.7 
-------------------------------  ----------  -------------  -----------  ----------- 
 AMO Pharma                        Unquoted    Health Care        8,526          1.6 
-------------------------------  ----------  -------------  -----------  ----------- 
 ReNeuron Group                      Quoted    Health Care        7,284          1.4 
-------------------------------  ----------  -------------  -----------  ----------- 
 Evofem Biosciences                  Quoted    Health Care        6,064          1.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 IDEX Biometrics                     Quoted     Technology        5,553          1.1 
-------------------------------  ----------  -------------  -----------  ----------- 
 Cequr                             Unquoted    Health Care        5,020          1.0 
-------------------------------  ----------  -------------  -----------  ----------- 
 Kind Consumer                     Unquoted        Staples        4,802          0.9 
-------------------------------  ----------  -------------  -----------  ----------- 
 Kuur Therapeutics (previously 
  Cell Medica)                     Unquoted    Health Care        4,247          0.8 
-------------------------------  ----------  -------------  -----------  ----------- 
 Mereo BioPharma Group               Quoted    Health Care        3,531          0.7 
-------------------------------  ----------  -------------  -----------  ----------- 
 American Financial Exchange       Unquoted     Financials        3,062          0.6 
-------------------------------  ----------  -------------  -----------  ----------- 
 Lignia Wood                       Unquoted    Industrials        2,981          0.6 
-------------------------------  ----------  -------------  -----------  ----------- 
 Psioxus                           Unquoted    Health Care        1,779          0.3 
-------------------------------  ----------  -------------  -----------  ----------- 
 Econic                            Unquoted    Industrials        1,440          0.3 
-------------------------------  ----------  -------------  -----------  ----------- 
 Ratesetter                        Unquoted     Financials        1,327          0.3 
-------------------------------  ----------  -------------  -----------  ----------- 
 Scifluor                          Unquoted    Health Care        1,230          0.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 Nexeon                            Unquoted    Industrials        1,182          0.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 Origin                            Unquoted    Health Care          968          0.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 Novabiotics                       Unquoted    Industrials          847          0.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 Bodle Technologies                Unquoted     Technology          766          0.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 Metaboards                        Unquoted     Technology          762          0.2 
-------------------------------  ----------  -------------  -----------  ----------- 
 NetScientific                       Quoted    Health Care          756          0.1 
-------------------------------  ----------  -------------  -----------  ----------- 
 Xeros Technology                    Quoted    Industrials          339          0.1 
-------------------------------  ----------  -------------  -----------  ----------- 
 Tissue Regenix Group                Quoted    Health Care           84            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 RM2 International                 Unquoted    Industrials           60            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Midatech Pharma                     Quoted    Health Care            2            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Drayson                           Unquoted     Technology            -            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Halosource                        Unquoted    Industrials            -            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Metalysis                         Unquoted    Industrials            -            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Oxsybio                           Unquoted    Health Care            -            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Precision Biopsy                  Unquoted    Health Care            -            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Sphere Medical                    Unquoted    Health Care            -            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Wath Investments                  Unquoted    Industrials            -            - 
-------------------------------  ----------  -------------  -----------  ----------- 
 Total investments:(1)                                          516,997        100.0 
----------------------------------------------------------  -----------  ----------- 

(1) Total investments comprise:

                                       GBP'000        % 
---------------------------------    ---------  ------- 
 Quoted on AIM                          11,996      2.3 
-----------------------------------  ---------  ------- 
 Listed on a recognised stock 
  exchange overseas                     34,598      6.7 
-----------------------------------  ---------  ------- 
 Quoted on Acquis Stock Exchange        80,811     15.6 
-----------------------------------  ---------  ------- 
 Unquoted                              389,592     75.4 
-----------------------------------  ---------  ------- 
 Total                                 516,997    100.0 
-----------------------------------  ---------  ------- 

Principal Risks and Uncertainties

The board has determined that the key risks for the Company are COVID-19 risk, gearing risk, performance risk, general valuation risk, portfolio specific valuation risk; investee company specific risk; portfolio concentration risk; Portfolio Manager and key man risk; outsourced service provider model risk; currency risk and cyber risk. These risks, as well as the emerging risks and uncertainties determined by the board, are set out on pages 21 to 25 of the annual report and accounts for the year ended 31 December 2019. These risks and uncertainties have not materially changed during the six months ended 30 June 2020 or since the annual report was published on 1 May 2020.

Going concern

Having assessed the principal risks and uncertainties, and the other matters discussed in connection with the viability statement as set out on page 26 of the published annual report and accounts for the year ended 31 December 2019, as well as considering the additional risks related to COVID-19, and where appropriate, action taken by the Portfolio Manager and Company's service providers in relation to those risks, the directors consider it appropriate to adopt the going concern basis in preparing the accounts.

Related party transactions

There have been no transactions with related parties that have materially affected the financial position or the performance of the Company during the six months ended 30 June 2020.

Directors' responsibility statement

The directors confirm that, to the best of their knowledge, this set of condensed financial statements has been prepared in accordance with United Kingdom Generally Accepted Accounting Practice and with the Statement of Recommended Practice, "Financial Statements of Investment Companies and Venture Capital Trusts" issued in October 2019 and that this Interim Management Report includes a fair review of the information required by 4.2.7R and 4.2.8R of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Income Statement

for the six months ended 30 June 2020 (unaudited)

                          (Unaudited)                    (Unaudited)                       (Audited) 
                      For the six months             For the six months                  For the year 
                      ended 30 June 2020             ended 30 June 2019             ended 30 December 2019 
                  Revenue   Capital     Total   Revenue    Capital       Total   Revenue    Capital       Total 
                  GBP'000   GBP'000   GBP'000   GBP'000    GBP'000     GBP'000   GBP'000    GBP'000     GBP'000 
Losses on 
 held at fair 
 value through 
 profit or 
 loss                   -  (34,134)  (34,134)         -  (226,207)   (226,207)         -  (421,175)   (421,175) 
Losses on 
 contracts              -         -         -         -    (2,827)     (2,827)         -    (9,373)     (9,373) 
 on foreign 
 exchange               -        18        18         -          -           -         -        (1)         (1) 
Income from 
 investments            -         -         -         -          -           -         -          -           - 
----------------  -------  --------  --------  --------  ---------  ----------  --------  ---------  ---------- 
Gross loss              -  (34,116)  (34,116)         -  (229,034)   (229,034)         -  (430,549)   (430,549) 
 fees               (669)         -     (669)         -          -           -         -          -           - 
 expenses           (703)         -     (703)   (1,193)          -     (1,193)   (3,115)          -     (3,115) 
----------------  -------  --------  --------  --------  ---------  ----------  --------  ---------  ---------- 
Net loss 
 before finance 
 costs and 
 taxation         (1,372)  (34,116)  (35,488)   (1,193)  (229,034)   (230,227)   (3,115)  (430,549)   (433,664) 
Finance costs     (1,076)         -   (1,076)   (1,480)          -     (1,480)   (2,841)          -     (2,841) 
----------------  -------  --------  --------  --------  ---------  ----------  --------  ---------  ---------- 
Loss before 
 taxation         (2,448)  (34,116)  (36,564)   (2,673)  (229,034)   (231,707)   (5,956)  (430,549)   (436,505) 
Taxation                -         -         -         -          -           -         -          -           - 
----------------  -------  --------  --------  --------  ---------  ----------  --------  ---------  ---------- 
Net loss 
 after taxation   (2,448)  (34,116)  (36,564)   (2,673)  (229,034)   (231,707)   (5,956)  (430,549)   (436,505) 
----------------  -------  --------  --------  --------  ---------  ----------  --------  ---------  ---------- 
Loss per 
 share (note 
 3)               (0.27)p   (3.75)p   (4.02)p   (0.30)p   (25.97)p    (26.27)p   (0.67)p   (48.08)p    (48.75)p 
----------------  -------  --------  --------  --------  ---------  ----------  --------  ---------  ---------- 

The "Total" column of this statement is the profit and loss account of the Company. The "Revenue" and "Capital" columns represent supplementary information prepared under guidance issued by The Association of Investment Companies. The Company has no other items of other comprehensive income, and therefore the net loss on ordinary activities after taxation is also the total comprehensive loss for the period.

All revenue and capital items in the above statement derive from continuing operations. No operations were acquired or discontinued in the period.

Statement of Changes in Equity

For the six months ended 30 June 2020 (unaudited)

                          share     Share     Capital    Revenue 
                        capital   premium    reserves    reserve     Total 
                        GBP'000   GBP'000     GBP'000    GBP'000   GBP'000 
At 31 December 2019       9,086   891,017   (436,934)   (13,740)   449,429 
Net loss                      -         -    (34,116)    (2,448)  (36,564) 
--------------------  ---------  --------  ----------  ---------  -------- 
At 30 June 2020           9,086   891,017   (471,050)   (16,188)   412,865 
--------------------  ---------  --------  ----------  ---------  -------- 

For the six months ended 30 June 2019 (unaudited)

                          share     Share     Capital    Revenue 
                        capital   premium    reserves    reserve      Total 
                        GBP'000   GBP'000     GBP'000    GBP'000    GBP'000 
At 31 December 2018       8,270   813,099     (6,385)    (7,784)    807,200 
Issue of shares             816    78,105           -          -     78,921 
Share issue costs             -     (186)           -          -      (186) 
Net loss                      -         -   (229,034)    (2,673)  (231,707) 
--------------------  ---------  --------  ----------  ---------  --------- 
At 30 June 2019           9,086   891,018   (235,419)   (10,457)    654,228 
--------------------  ---------  --------  ----------  ---------  --------- 

For the year ended 31 December 2019 (audited)

                          share     Share     Capital    Revenue 
                        capital   premium    reserves    reserve       Total 
                        GBP'000   GBP'000     GBP'000    GBP'000     GBP'000 
At 31 December 2018       8,270   813,099     (6,385)    (7,784)     807,200 
Issue of shares             816    78,105           -          -      78,921 
Share issue costs             -     (187)           -          -       (187) 
Net loss                      -         -   (430,549)    (5,956)   (436,505) 
--------------------  ---------  --------  ----------  ---------  ---------- 
At 31 December 2019       9,086   891,017   (436,934)   (13,740)     449,429 
--------------------  ---------  --------  ----------  ---------  ---------- 

Statement of Financial Position

at 30 June 2020 (unaudited)

                                         (Unaudited)  (Unaudited)    (Audited) 
                                             30 June      30 June  31 December 
                                                2020         2019         2019 
                                             GBP'000      GBP'000      GBP'000 
Fixed assets 
Investments held at fair value through 
 profit or loss (note 4)                     516,997      777,866      561,115 
---------------------------------------  -----------  -----------  ----------- 
Current assets 
Debtors                                          606           37           30 
Cash at bank and in hand                       3,577            -        2,234 
Derivative financial instruments held 
 at fair value through profit or loss              -          725            - 
---------------------------------------  -----------  -----------  ----------- 
                                               4,183          762        2,264 
---------------------------------------  -----------  -----------  ----------- 
Current liabilities 
Creditors: amounts falling due within 
 one year (note 5)                         (108,315)    (116,921)      (1,050) 
Derivative financial instruments held 
 at fair value through profit or loss              -      (7,479)            - 
---------------------------------------  -----------  -----------  ----------- 
                                           (108,315)    (124,400)      (1,050) 
---------------------------------------  -----------  -----------  ----------- 
Net current (liabilities)/assets           (104,132)    (123,638)        1,214 
---------------------------------------  -----------  -----------  ----------- 
Total assets less current liabilities        412,865      654,228      562,329 
Creditors: amounts falling due after 
 more than one year (note 6)                       -            -    (112,900) 
---------------------------------------  -----------  -----------  ----------- 
Net assets                                   412,865      654,228      449,429 
---------------------------------------  -----------  -----------  ----------- 
Capital and reserves 
Called-up share capital (note 7)               9,086        9,086        9,086 
Share premium                                891,017      891,018      891,017 
Capital reserves                           (471,050)    (235,419)    (436,934) 
Revenue reserve                             (16,188)     (10,457)     (13,740) 
---------------------------------------  -----------  -----------  ----------- 
Total equity shareholders' funds             412,865      654,228      449,429 
---------------------------------------  -----------  -----------  ----------- 
Net asset value per share (note 8)            45.44p       72.00p       49.46p 

Registered in England and Wales as a public company limited by shares

Company registration number: 09405653

Cash Flow Statement

for the six months ended 30 June 2020 (unaudited)

                                         (Unaudited)   (Unaudited)    (Audited) 
                                         For the six   For the six      For the 
                                        months ended  months ended   year ended 
                                             30 June       30 June  31 December 
                                                2020          2019         2019 
                                             GBP'000       GBP'000      GBP'000 
Cash flows from operating activities 
Loss before finance costs and 
 taxation                                   (35,488)     (230,227)    (433,664) 
Adjustments for: 
Losses on investment held at 
 fair value through profit or 
 loss                                         34,134       226,207      421,175 
Net movement in forward currency 
 contracts                                         -         2,827        9,373 
Net movement in foreign exchange                (18)             -            1 
Increase in debtors                             (20)          (22)         (19) 
Increase in creditors                            263           312          578 
--------------------------------------  ------------  ------------  ----------- 
Net cash flow from operating 
 activities                                  (1,129)         (903)      (2,556) 
--------------------------------------  ------------  ------------  ----------- 
Cash flows from investment activities 
Purchases of investments                     (2,012)      (99,008)    (137,143) 
Proceeds from sales of investments            11,440       131,117      191,387 
Settlement of foreign forward 
 currency contracts                                -       (1,701)     (15,349) 
--------------------------------------  ------------  ------------  ----------- 
Net cash flow from investment 
 activities                                    9,428        30,408       38,895 
--------------------------------------  ------------  ------------  ----------- 
Cash flows from financing activities 
Issue of shares                                    -         6,000        6,000 
Share issue costs                                  -         (185)        (187) 
Finance costs                                (1,106)       (1,480)      (2,852) 
Repayment of loan                            (5,868)             -            - 
--------------------------------------  ------------  ------------  ----------- 
Net cash flow from financing 
 activities                                  (6,974)         4,335        2,961 
--------------------------------------  ------------  ------------  ----------- 
Net increase in cash and cash 
 equivalents                                   1,325        33,840       39,300 
Effect of foreign exchange                        18             -            - 
--------------------------------------  ------------  ------------  ----------- 
Change in cash and cash equivalents            1,343        33,840       39,300 
Cash and cash equivalents at 
 the beginning of the period                   2,234     (149,966)    (149,966) 
Reclassification of overdraft 
 liability(1)                                      -             -      112,900 
--------------------------------------  ------------  ------------  ----------- 
Cash and cash equivalents at 
 the end of the period                         3,577     (116,126)        2,234 
--------------------------------------  ------------  ------------  ----------- 

(1) Following the amendments to the term facility agreement, the overdraft was reclassified as a loan.

Notes to the Accounts

   1.         Financial Statements 

The information contained within the accounts in this half year report has not been audited or reviewed by the Company's independent auditor.

The figures and financial information for the year ended 31 December 2019 are extracted from the latest published accounts of the Company and do not constitute statutory accounts for that year. Those accounts have been delivered to the Registrar of Companies and included the report of the auditor which was unqualified and did not contain a statement under either section 498(2) or 498(3) of the Companies Act 2006.

   2.         Accounting policies 

Basis of accounting

The accounts have been prepared in accordance with United Kingdom Generally Accepted Accounting Practice and with the Statement of Recommend Practice "Financial Statements of Investment Trust Companies and Venture Capital Trusts" issued by the Association of Investment Companies in October 2019.

All of the Company's operations are of a continuing nature.

The accounting policies applied to these accounts are consistent with those applied in the accounts for the year ended 31 December 2019. In particular the policy on valuation of investments is consistent with that detailed in note 1(b) to the accounts for the year ended 31 December 2019, presented on pages 54 and 55 of the annual report.

   3.         Loss per share 
                                        (Unaudited)   (Unaudited)    (Audited) 
                                        For the six   For the six      For the 
                                       months ended  months ended   year ended 
                                            30 June       30 June  31 December 
                                               2020          2019         2019 
                                            GBP'000       GBP'000      GBP'000 
Revenue loss                                (2,448)       (2,673)      (5,956) 
Capital loss                               (34,116)     (229,034)    (430,549) 
-------------------------------------  ------------  ------------  ----------- 
Total loss                                 (36,564)     (231,707)    (436,505) 
-------------------------------------  ------------  ------------  ----------- 
Weighted average number of shares in 
 issue during the period                908,639,238   882,027,553  895,442,758 
Revenue loss per share                      (0.27)p       (0.30)p      (0.67)p 
Capital loss per share                      (3.75)p      (25.97)p     (48.08)p 
-------------------------------------  ------------  ------------  ----------- 
Total loss per share                        (4.02)p      (26.27)p     (48.75)p 
-------------------------------------  ------------  ------------  ----------- 
   4.         Investments held at fair value through profit or loss 
   (a)        Movement in investments 
                                             (Unaudited)   (Unaudited) 
                                             For the six   For the six    (Audited) 
                                            months ended  months ended      For the 
                                                                         year ended 
                                                 30 June       30 June  31 December 
                                                    2020          2019         2019 
                                                 GBP'000       GBP'000      GBP'000 
Opening book cost                                820,226       912,049      912,049 
Opening investment holding (losses)/gains      (259,111)        51,564       51,564 
------------------------------------------  ------------  ------------  ----------- 
Opening valuation                                561,115       963,613      963,613 
Purchases at cost                                  2,012       171,511      137,143 
Investments received as consideration 
 for share issue                                       -             -       72,921 
Sales proceeds                                  (11,996)     (131,051)    (191,387) 
Losses on investments held at fair 
 value through profit or loss                   (34,134)     (226,207)    (421,175) 
------------------------------------------  ------------  ------------  ----------- 
Closing valuation                                516,997       777,866      561,115 
------------------------------------------  ------------  ------------  ----------- 
Closing book cost                                809,139       961,509      820,226 
Closing investment holding losses              (292,142)     (183,643)    (259,111) 
------------------------------------------  ------------  ------------  ----------- 
Total investments held at fair value 
 through profit or loss                          516,997       777,866      561,115 
------------------------------------------  ------------  ------------  ----------- 

(b) Material revaluations of unquoted investments, including investments quoted in inactive markets, during the period

                           Opening                Closing 
                         valuation              valuation 
                                at                     at 
                       31 December   Valuation    30 June 
                          2019 (1)  adjustment       2020 
Investment                 GBP'000     GBP'000    GBP'000 
Inivata                     18,006       6,957     24,963 
Atom Bank                   80,866    (24,094)     56,772 
Mission Therapeutics        15,648     (5,531)     10,117 
Ratesetter                   6,709     (5,382)      1,327 
---------------------  -----------  ----------  --------- 

(1) Based on the closing holding at opening prices.

There were no material disposals of unquoted investments during the period.

   5.         Creditors: amounts falling due within one year 
                               (Unaudited)  (Unaudited)    (Audited) 
                                   30 June      30 June  31 December 
                                      2020         2019         2019 
                                   GBP'000      GBP'000      GBP'000 
Bank loan                          107,032            -            - 
Other creditors and accruals         1,283          795        1,050 
Bank overdraft                           -      116,126            - 
-----------------------------  -----------  -----------  ----------- 
                                   108,315      116,921        1,050 
-----------------------------  -----------  -----------  ----------- 

On 13 December 2019, the Company ended its term facility and arranged a term loan to 15 January 2021. The loan is secured on all the Company's assets. The agreement requires that, subject to an allowance for operating expenses, the proceeds of Private Asset sales must be used to make loan repayments, which cannot be redrawn. Furthermore, the Company may not make further Private Asset investments until certain prepayment hurdles have been met. Interest payable will be calculated at LIBOR, for one month or other agreed loan period, plus a margin of 1.5%.

   6.         Creditors: amounts falling due after more than one year 
            (Unaudited)  (Unaudited)    (Audited) 
                30 June      30 June  31 December 
                   2020         2019         2019 
                GBP'000      GBP'000      GBP'000 
Bank loan             -            -      112,900 
----------  -----------  -----------  ----------- 

The bank loan is drawn under an agreement which expires on 15 January 2021. At 30 June 2020, the loan has been redesignated as a loan falling due within one year, and further details are given in note 5 above.

   7.         Called-up share capital 
                                          (Unaudited)   (Unaudited)     (Audited) 
                                          For the six   For the six       For the 
                                                                       year ended 
                                         months ended  months ended   31 December 
                                         30 June 2020  30 June 2019          2019 
                                              GBP'000       GBP'000       GBP'000 
Ordinary shares allotted, called up 
 and fully paid: 
Ordinary shares of 1p each: 
Opening balance of 908,639,238 (2019: 
 827,000,000) shares                            9,086         8,270         8,270 
Issue of nil (2019: 81,639,238) shares              -           816           816 
---------------------------------------  ------------  ------------  ------------ 
Closing balance of 908,639,238 (2019: 
 908,639,238) shares                            9,086         9,086         9,086 
---------------------------------------  ------------  ------------  ------------ 
   8.         Net asset value per share 
                                          (Unaudited)  (Unaudited)    (Audited) 
                                              30 June      30 June  31 December 
                                                 2020         2019         2019 
Net assets attributable to shareholders 
 (GBP'000)                                    412,865      654,228      449,429 
----------------------------------------  -----------  -----------  ----------- 
Shares in issue at the period end         908,639,238  908,639,238  908,639,238 
----------------------------------------  -----------  -----------  ----------- 
Net asset value per share                      45.44p       72.00p       49.46p 
----------------------------------------  -----------  -----------  ----------- 
   9.         Disclosures regarding financial instruments measured at fair value 

The Company's financial instruments within the scope of FRS 102 that are held at fair value comprise its investment portfolio and any derivative financial instruments.

FRS 102 requires that financial instruments held at fair value are categorised into a hierarchy consisting of the three levels below. A fair value measurement is categorised in its entirety on the basis of the lowest level input that is significant to the fair value measurement.

Level 1 - valued using unadjusted quoted prices in active markets for identical assets.

Level 2 - valued using observable inputs other than quoted prices included within Level 1.

Level 3 - valued using inputs that are unobservable.

The Company's investment portfolio and derivative financial instruments were categorised as follows:

                                           30 June 2020 (unaudited) 
                                     Level 1   Level 2   Level 3     Total 
                                     GBP'000   GBP'000   GBP'000   GBP'000 
 Investments in equities - 
  quoted                              46,594         -    80,811   127,405 
 - unquoted                                -         -   389,592   389,592 
----------------------------------  --------  --------  --------  -------- 
 Total                                46,594         -   470,403   516,997 
----------------------------------  --------  --------  --------  -------- 
                                           30 June 2019 (unaudited) 
                                     Level 1   Level 2   Level 3     Total 
                                     GBP'000   GBP'000   GBP'000   GBP'000 
 Investments in equities - 
  quoted                             103,462         -   156,960   260,422 
 - unquoted                                -         -   517,444   517,444 
 Derivative financial instruments 
 forward currency contracts                -   (6,754)         -   (6,754) 
----------------------------------  --------  --------  --------  -------- 
 Total                               103,462   (6,754)   674,404   771,112 
----------------------------------  --------  --------  --------  -------- 
                                          31 December 2019 (audited) 
                                     Level 1   Level 2   Level 3     Total 
                                     GBP'000   GBP'000   GBP'000   GBP'000 
 Investments in equities - 
  quoted                              53,476         -    80,811   134,287 
 - unquoted                                -         -   426,828   426,828 
----------------------------------  --------  --------  --------  -------- 
 Total                                53,476         -   507,639   561,115 
----------------------------------  --------  --------  --------  -------- 

There have been no transfers between Levels 1, 2 or 3 during the period (period ended 30 June 2019 and year ended 31 December 2019: nil).

10. Events after the interim date that have not been reflected in the financial statements for the interim period

Acquisition of RateSetter

On 14 September 2020, Metro Bank PLC announced the acquisition of RateSetter, following receipt of shareholders' and regulatory approval. Under the terms of the acquisition, the Company expects to receive a total consideration which is marginally above its holding value of GBP1,327,000 as at 30 June 2020.

The directors have evaluated the period since the interim date and have not noted any other events which have not been reflected in the financial statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

September 30, 2020 02:00 ET (06:00 GMT)

Woodford Patient Capital (LSE:WPCT)
Gráfica de Acción Histórica
De Ago 2021 a Sep 2021 Haga Click aquí para más Gráficas Woodford Patient Capital.
Woodford Patient Capital (LSE:WPCT)
Gráfica de Acción Histórica
De Sep 2020 a Sep 2021 Haga Click aquí para más Gráficas Woodford Patient Capital.